ROSALEE UNWIN, FNP-C
Family Nurse Practitioner · CHARLESTON, SC
Individual Active NPI 1336555234
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 528 | 128,306 | $11,111,026 | $3,697,683 | $2,931,097 |
| 2023 | 767 | 207,328 | $16,957,337 | $5,341,513 | $4,243,510 |
| 2022 | 651 | 189,629 | $15,629,532 | $5,265,231 | $4,185,781 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J3111 | Injection, romosozumab-aqqg, 1 mg | 31,500 | $11 | $8 |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 10,200 | $22 | $17 |
| J1306 | Injection, inclisiran, 1 mg | 8,236 | $12 | $9 |
| J0897 | Injection, denosumab, 1 mg | 6,840 | $25 | $20 |
| J2356 | Injection, tezepelumab-ekko, 1 mg | 6,720 | $17 | $14 |
| J2182 | Injection, mepolizumab, 1 mg | 5,800 | $30 | $24 |
| J2357 | Injection, omalizumab, 5 mg | 4,305 | $38 | $30 |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 2,720 | $43 | $34 |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 2,480 | $31 | $25 |
| J3245 | Injection, tildrakizumab, 1 mg | 1,300 | $137 | $109 |
| J0517 | Injection, benralizumab, 1 mg | 750 | $165 | $131 |
| 96372 | Injection of drug or substance under skin or into muscle | 469 | $11 | $9 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Family Nurse Practitioner | 363LF0000X | ✓ | 23797 | SC |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- No
Other Family Nurse Practitioner providers in South Carolina
- NPI 1720554132
- NPI 1639543689
- NPI 1447972963
- NPI 1588819205
- NPI 1295616894
- NPI 1891123345
- NPI 1225558687
- NPI 1932869153
See all Family Nurse Practitioner providers in South Carolina →
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.